Production (Stage)
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.09
-$0.15-12.10%
OTC PK
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 976.04M | 976.04M | 953.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 976.04M | 976.04M | 953.16M |
| Cost of Revenue | -- | -- | 360.45M | 360.45M | 359.74M |
| Gross Profit | -- | -- | 615.58M | 615.58M | 593.42M |
| SG&A Expenses | -- | -- | 414.69M | 414.69M | 402.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 4.49M | 4.49M | 1.98M |
| Total Operating Expenses | -- | -- | 779.63M | 779.63M | 764.58M |
| Operating Income | -- | -- | 196.41M | 196.41M | 188.58M |
| Income Before Tax | -- | -- | 117.58M | 121.12M | 104.71M |
| Income Tax Expenses | -- | -- | 40.75M | 40.75M | 37.40M |
| Earnings from Continuing Operations | -- | -- | 76.83 | 80.37 | 67.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -3.53M | -3.53M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 76.83M | 76.83M | 63.77M |
| EBIT | -- | -- | 196.41M | 196.41M | 188.58M |
| EBITDA | -- | -- | 210.84M | 210.84M | 203.00M |
| EPS Basic | -- | -- | 0.08 | 0.08 | 0.07 |
| Normalized Basic EPS | -- | -- | 0.08 | 0.08 | 0.07 |
| EPS Diluted | -- | -- | 0.08 | 0.08 | 0.07 |
| Normalized Diluted EPS | -- | -- | 0.08 | 0.08 | 0.07 |
| Average Basic Shares Outstanding | -- | -- | 3.79B | 3.76B | 3.79B |
| Average Diluted Shares Outstanding | -- | -- | 3.79B | 3.76B | 3.79B |
| Dividend Per Share | -- | -- | 0.03 | 0.03 | 0.05 |
| Payout Ratio | -- | -- | 59.52% | 59.52% | 70.00% |